Treatment of amyotrophic lateral sclerosis using placental stem cells
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-063/00
A61K-035/50
A61K-045/06
출원번호
US-0343283
(2012-09-10)
등록번호
US-9925221
(2018-03-27)
국제출원번호
PCT/US2012/054493
(2012-09-10)
§371/§102 date
20141027
(20141027)
국제공개번호
WO2013/055476
(2013-04-18)
발명자
/ 주소
Hariri, Robert J.
Gurney, Jodi P.
출원인 / 주소
Celularity, Inc.
대리인 / 주소
Celularity, Inc.
인용정보
피인용 횟수 :
0인용 특허 :
179
초록▼
Provided herein are methods of treatment of an individual having amyotrophic lateral sclerosis, comprising administering to the individual a therapeutically effective amount of placental stem cells, e.g., tissue culture surface-adherent placental stem cells (PDACs). In one aspect, provided herein is
Provided herein are methods of treatment of an individual having amyotrophic lateral sclerosis, comprising administering to the individual a therapeutically effective amount of placental stem cells, e.g., tissue culture surface-adherent placental stem cells (PDACs). In one aspect, provided herein is a method of treating amyotrophic lateral sclerosis (ALS) comprising administering to an individual having ALS a therapeutically effective amount of placental stem cells. In certain embodiments, “therapeutically effective” means an amount effective to reduce or ameliorate one or more symptoms of ALS.
대표청구항▼
1. A method of treating an individual having amyotrophic lateral sclerosis (ALS), comprising administering to the individual a therapeutically effective amount of placental stem cells, wherein the therapeutically effective amount is an amount sufficient to detectably reduce or ameliorate one or more
1. A method of treating an individual having amyotrophic lateral sclerosis (ALS), comprising administering to the individual a therapeutically effective amount of placental stem cells, wherein the therapeutically effective amount is an amount sufficient to detectably reduce or ameliorate one or more symptoms of said ALS, and wherein administration occurs twice per month every one, two, or three months. 2. The method of claim 1, further comprising monitoring one or more of said symptoms in said patient; and administering a second dose of placental stem cells when said one or more symptoms begins to worsen. 3. The method of claim 1, wherein said one or more symptoms comprise difficulty lifting the front part of the foot; difficulty lifting the toes; weakness in one or both legs; weakness in one or both feet; weakness in one or both ankles; hand weakness; hand clumsiness; slurring of speech; trouble swallowing; muscle cramps; twitching in one or both arms; twitching in one or both shoulders and/or twitching of the tongue. 4. The method of claim 1, additionally comprising administering a second therapeutic composition, wherein said second therapeutic composition is riluzole, ceftriaxone, dexpramipexole, creatine+tamoxifen, rasagiline, pioglitazone, arimoclomol, pyrimethamine, trantinoin+pioglitazone, or an antisense molecule or interfering RNA directed against an RNA encoding superoxide dismutase. 5. The method of claim 2, wherein said monitoring comprises monitoring over between 1 and 7 days post-administration. 6. The method of claim 2, wherein said monitoring comprises monitoring over between 7 and 28 days post administration. 7. The method of claim 2, wherein said monitoring comprises monitoring over between 1 and 28 weeks post-administration. 8. The method of claim 1, wherein said placental stem cells are CD10+, CD34−, CD105+ placental stem cells. 9. The method of claim 8, wherein said placental stem cells are additionally CD200+. 10. The method of claim 8, wherein said placental stem cells are additionally CD45− and CD90+. 11. The method of claim 8, wherein said placental stem cells are additionally CD80− and CD86−. 12. The method of claim 1 or claim 2, wherein said placental stem cells express CD200 and do not express HLA-G; or express CD73, CD105, and CD200; or express CD200 and OCT-4; or express CD73 and CD105 and do not express HLA-G. 13. The method of claim 8, wherein said placental stem cells are HLA-A,B,C+. 14. The method of claim 1, wherein said placental stem cells are formulated to be administered locally. 15. The method of claim 1, wherein said placental stem cells are formulated to be administered systemically, intravenously, intraarterially, subcutaneously, or intrathecally. 16. The method of claim 1, wherein said therapeutically effective amount comprises at least 1×107 placental stem cells per administration. 17. The method of claim 1, wherein said therapeutically effective amount comprises at least 1×108 placental stem cells per administration. 18. The method of claim 1, wherein said therapeutically effective amount comprises at least 2×108 placental stem cells per administration. 19. The method of claim 1, wherein said therapeutically effective amount comprises at least 1×109 placental stem cells per administration. 20. The method of claim 2, wherein said placental stem cells are CD10+, CD34−, CD105+, and CD200+.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (179)
Pittenger Mark F., Adipogenic differentiation of human mesenchymal stem cells.
Kuypers Franciscus A. ; Cole Robert B. ; Meyst Richard P. ; Gorton Lanny A. ; Wright James I., Apparatus and method for collecting blood from an umbilical cord.
Kuypers Franciscus A. ; Cole Robert B. ; Meyst Richard P. ; Gorton Lanny A. ; Wright James I., Apparatus and method for collecting blood from an umbilical cord.
Kuypers Franciscus A. ; Cole Robert B. ; Meyst Richard P. ; Gorton Lanny A. ; Wright James I., Apparatus and method for collecting blood from an umbilical cord.
Sanchez-Ramos, Juan; Song, Shijie; Janssen, William; Sanberg, Paul; Freeman, Thomas, Bone marrow cells as a source of neurons for brain and spinal cord repair.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Heidaran, Mohammad; Wang, Jia-Lun; Ye, Qian; Zeitlin, Andrew; Dulaney, Colleen Suzanne, Co-culture of placental stem cells and stem cells from a second source.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Compositions containing cultured mitotic human stem cells.
Caplan Arnold I. ; Haynesworth Stephen E. ; Gerson Stanton L. ; Lazarus Hillard M., Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells.
Bauer S. Christopher ; Abrams Mark Allen ; Braford-Goldberg Sarah Ruth ; Caparon Maire Helena ; Easton Alan Michael ; Klein Barbara Kure ; McKearn John Patrick ; Olins Peter O. ; Paik Kumnan ; Thomas, Ex-vivo expansion of stem cells using combinations of interleukin-3 (IL-3) variants and other cytokines.
Bjornson Christopher R. ; Rietze Rod L.,AUX ; Reynolds Brent A.,CAX ; Vescovi Angelo L.,ITX, Generation of hematopoietic cells from multipotent neural stem cells.
Nakahata Tatsutoshi (Matsumoto JPX) Kawano Genji (Kamakura JPX) Sudo Tetsuo (Kamakura JPX) Kojima Katsuaki (Yokohama JPX), Hematopoietic stem cell growth-promoting compositions containing a fibroblast-derived fragment of fibronectin and a grow.
Rubinstein Pablo ; Coelho Philip Henry ; Stevens Cladd E., High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjuncti.
Janice M. Davis-Sproul ; Mark Aaron Moorman ; Renee Marie McNeil ; Donald William Simonetti, Jr. ; Lora Catherine Hammill ; Stewart Craig, Human mesenchymal stem cells.
Srour Edward (Indianapolis IN) Zanjani Esmail (Reno NV) Brandt John E. (Indianapolis IN) Hoffman Ronald (Indianapolis IN), Human stem cell compositions and methods.
Tsukamoto Ann (Palo Alto CA) Baum Charles M. (Mountain View CA) Aihara Yukoh (Yokohama JPX) Weissman Irving (Palo Alto CA), Identification and isolation of human hematopoietic stem cells.
Prockop Darwin J. ; Pereira Ruth F. ; Leeper Dennis B. ; O'Hara Michael D., Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects.
Edward A. Boyse ; Hal E. Broxmeyer ; Gordon W. Douglas, Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood.
Boyse Edward A. (Tucson AZ) Broxmeyer Hal E. (Indianapolis IN) Douglas Gordon W. (New York NY), Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of the.
Kevin R. McIntosh ; Joseph D. Mosca ; Elena N. Klyushnenkova, Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
McIntosh Kevin R. ; Mosca Joseph D. ; Klyushnenkova Elena N., Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
McIntosh, Kevin R.; Mosca, Joseph D.; Klyushnenkova, Elena, Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
Caplan Arnold I. (1300 Oakridge Dr. Cleveland Heights OH 44121) Haynesworth Stephen E. (3643 Antisdale Rd. Cleveland Heights OH 44118), Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultur.
Caplan Arnold I. (1300 Oakridge Dr. Cleveland Heights OH 44121) Haynesworth Stephen E. (3643 Antisdale Rd. Cleveland Heights OH 44118), Method for treating connective tissue disorders.
Murray Lesley (San Jose CA) Sutherland D. Robert (Oakville CAX), Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby an.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI) Schwartz Richard M. (Ann Arbor MI), Methods and compositions for the ex vivo replication of human hematopoietic stem cells.
Emerson Stephen G. ; Clarke Michael F. ; Palsson Bernhard O., Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 sec.
Fei Rui G. (Seattle WA) Heimfeld Shelly (Woodinville WA) Minshall Billy W. (Mill Creek WA) Berenson Ronald J. (Mercer Island WA), Methods and device for culturing human hematopoietic cells and their precursors.
Anderson David J. ; Shah Nirao M., Methods for differentiating neural stem cells to neurons or smooth muscle cells using TGT-.beta. super family growth factors.
Csete Marie ; Doyle John ; Wold Barbara, Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells.
Palsson Bernhard O. (Ann Arbor MI) Armstrong R. Douglas (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Emerson Stephen G. (Ann Arbor MI), Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Methods for the ex vivo replication of human stem cells and/or expansion of human progenitor cells.
Atala, Anthony; De Coppi, Paolo, Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof.
Hill Beth Louise ; Rozler Elen ; Chen Benjamin P., Methods of obtaining compositions enriched for hematopoietic stem cells, antibodies for use therein, compositions derived therefrom and methods of use thereof.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Methods, compositions and devices for growing human hematopoietic cells.
Palsson Bernhard O. ; Emerson Stephen G. ; Schwartz Richard M., Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells.
Hariri,Robert J.; Stirling,David I.; Moutouh De Parseval,Laure A.; Chan,Kyle W. H., Modulation of stem and progenitor cell differentiation, assays, and uses thereof.
Boyse Edward A. (New York NY) Broxmeyer Hal E. (Indianapolis IN) Douglas Gordon W. (New York NY), Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood.
Stern David M. (Great Neck NY) Oz Mehmet C. (Fort Lee NJ) Nowygrod Roman (Teaneck NJ) Koga Shin (New York NY) Pinsky David J. (Riverdale NY), Solution for prolonged organ preservation.
McIntosh, Kevin; Klyushnenkova, Elena, Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation.
Gerson Stanton L. (Pepper Pike OH) Caplan Arnold I. (Cleveland Heights OH) Haynesworth Stephen E. (Cleveland Heights OH), Transduced mesenchymal stem cells.
Messina, Darin J.; Mistry, Sanjay; Hong, L. S. Klaudyne; Kramer, Brian C.; Romanko, Michael J., Treatment of Parkinson's disease and related disorders using postpartum derived cells.
Messina, Darin J.; Mistry, Sanjay; Hong, L. S. Klaudyne; Kramer, Brian C.; Romanko, Michael J.; Gosiewska, Anna, Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells.
Hessel Stephen R. (Fountain Valley CA) Young H. Theodore (Lake Forest CA) Katz Michael (Richmond CA), Umbilical cord clamping, cutting, and blood collecting device and method.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.